Skip to content

Antiseptic Irrigation for Pleural Infection

Antiseptic Pleural Irrigation for Patients With Pleural Infection

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04761133
Enrollment
36
Registered
2021-02-18
Start date
2021-03-04
Completion date
2021-08-15
Last updated
2022-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pleural Infection

Brief summary

The antiseptic povidone-iodine can safely be instilled into the pleural for the purpose of pleurodesis. Pleural irrigation with antiseptics is used in adults with open drainage for chronic empyema and has been described in the acute management of paediatric pleural infection. This study will investigate the safety and usefulness of povidone-iodine pleural irrigation in 15 eligible patients recruited to the Pleural Infection Cohort Study (PICS) with acute pleural infection. A matched control group will be used and will be composed of 15 patients previously recruited to PICS without receiving povidone-iodine pleural irrigation.

Detailed description

Pleural infection is a condition that requires hospitalization for management and is associated with significant in-hospital morbidity and mortality. Predictors of poor outcome include advancing age, poor nutrition, hospital-acquired infection and impaired renal function. Medical management is centred on appropriate antibiotic treatment and fluid drainage usually by the means of an intercostal tube. Up to 30% of patients fail medical treatment and referred for surgery. A recent systematic review of adults patient with pleural infection has shown that the demographics of patients with pleural infection are different in patients from high-income vs lower income countries; the latter being of younger age and lower comorbidity burden. However, the results of the review did not show significant differences in patient outcomes. The same systematic review pointed to the need for more data from patients residing in lower income countries given that the majority of data is contributed by studies from higher income countries. This platform study aims to prospectively investigate the incidence of pleural infection in a large tertiary centre gathering demographic and clinical data about patients recruited. In addition, the study will examine the different treatment offered and how this related to in-hospital outcomes (length of hospital stay, rate of referral to surgery and mortality). The study will be designed as a modified trial within cohort (TwiC) study. PICS will primarily aim to recruit patients prospectively to gather clinical and demographic data on patients admitted with pleural infection in addition to clinical data on tests performed and treatments received as part of the standard care. The in-patient outcomes will be recorded at the time of discharge data or death, whichever is earlier. Within the TWIC design, PICS will be a platform for recruiting patients to interventional trials for eligible patients within the cohort. As a planned sub-study, pleural antiseptics will be trialed within a subset of patients enrolled. The antiseptic povidone-iodine can safely be instilled into the pleural for the purpose of pleurodesis. Pleural irrigation with antiseptics is used in adults with open drainage for chronic empyema and has been described in the acute management of paediatric pleural infection. This sub-study will investigate the safety and usefulness of povidone-iodine pleural irrigation in 15 eligible adult patients recruited to PICS with acute pleural infection. A matched control group will be used and will be composed of 15 patients previously recruited to PICS without receiving povidone-iodine pleural irrigation.

Interventions

DRUGPovidone-Iodine pleural irrigation

Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients admitted to hospital with pleural infection and had a chest tube inserted for treatment of the infection. Pleural infection will be defined by the presence of one of the following: a) the presence of pus in the pleural space; b) positive pleural fluid gram stain or culture; or c) pleural fluid pH \< 7.2 or pleural fluid glucose \< 40 mg/dL in the setting of acute respiratory infection. * Pleural collection is unilocular on pre-drainage imaging. Presence of septations on ultrasound examination is allowed.

Exclusion criteria

* Known or suspected thyroid disease * Allergy to iodine * Persistent large collection on follow up imaging 24-48 of post tube insertion that requires another drainage procedure

Design outcomes

Primary

MeasureTime frameDescription
Incidence of adverse eventsWithin 24 hours after the second application of the study medicationNumber of subjects with any adverse event (new chest pain, fever, dyspnoea or oxygen desaturation)
Time to chest tube removalUp to 8 weeksNumber of days from tube insertion to tube removal

Secondary

MeasureTime frameDescription
Time to defervescenceUp to 8 weeksNumbers of days until resolution of fever
Length of hospital stayUp to 8 weeksNumber of days from admission/diagnosis until discharge from hospital
Incidence of need for additional aspiration/tubesUp to 8 weeksNumber of patients requiring additional drainage procedures during hospital admission
Incidence of medical treatment of failureUp to 8 weeksNumber of patients requiring surgical intervention

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026